ZYN002 ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
203	22q11.2 deletion syndrome	1
206	Fragile X syndrome	3

203. 22q11.2 deletion syndrome

Clinical trials : 5 / Drugs : 7 - (DrugBank : 1) / Drug target genes : 14 - Drug target pathways : 23

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05149898 (ClinicalTrials.gov)	March 3, 2020	5/10/2021	Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome	Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome	22Q Deletion Syndrome	Drug: ZYN002	Zynerba Pharmaceuticals, Inc.	NULL	Completed	4 Years	17 Years	All	20	Phase 1/Phase 2	United States;Australia

206. Fragile X syndrome

Clinical trials : 108 / Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04977986 (ClinicalTrials.gov)	September 13, 2021	20/7/2021	Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome	A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT	Fragile X Syndrome	Drug: ZYN002 - transdermal gel;Drug: Placebo	Zynerba Pharmaceuticals, Inc.	NULL	Recruiting	3 Years	23 Years	All	204	Phase 3	United States;Australia;Ireland;United Kingdom
2	NCT03614663 (ClinicalTrials.gov)	June 12, 2018	10/7/2018	Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)	A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome	Fragile X Syndrome	Drug: ZYN002 - CBD Transdermal Gel;Other: Placebo Transdermal Gel	Zynerba Pharmaceuticals, Inc.	NULL	Completed	3 Years	17 Years	All	212	Phase 2/Phase 3	United States;Australia;New Zealand
3	EUCTR2021-002542-33-IE (EUCTR)		10/08/2021	Effects and Safety of Test drug ZYN002, applied as a gel onto the skin of children and adolescents with a certain hereditary disease called Fragile X Syndrome	A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome - RECONNECT - RECONNECT	Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X mental retardation protein (FMRP), an RNA-binding protein and the gene product of the FMR1 gene. FXS is most commonly caused by silencing of the FMR1 gene due to a trinucleotide repeat expansion. In FXS patients, the relative absence of functional FMRP is associated with critical impairments in neurodevelopment and learning, as well as disruption to other neuronal and non-neuronal functions. MedDRA version: 20.1;Level: PT;Classification code 10017324;Term: Fragile X syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Code: ZYN002 INN or Proposed INN: n/a Other descriptive name: CANNABIDIOL	Zynerba Pharmaceuticals, Inc.	NULL	NA			Female: yes Male: yes	204	Phase 3	United States;Ireland;Australia;United Kingdom